Roivant Sciences Ltd. — Form 10-Q Summary
Reporting period: Fiscal third quarter and nine months ended December 31, 2023 (fiscal year ending March 31, 2024). The request metadata says “2022 Q3,” but the filing itself covers the period ended December 31, 2023.
Business context and reporting period
Roivant is a commercial-stage biopharmaceutical company that develops medicines through subsidiaries (“Vants”). Its portfolio includes VTAMA for psoriasis, in development for atopic dermatitis, and clinical-stage candidates including batoclimab, IMVT-1402, brepocitinib and namilumab. The company reports one consolidated operating segment. Financial amounts below are in U.S. dollars; unless stated otherwise, figures are millions.
Key financial metrics
| Metric | Three months ended Dec. 31, 2023 | Nine months ended Dec. 31, 2023 | Comparable 2022 period |
|---|---|---|---|
| Revenue, net | $37.1 | $95.9 | $17.1 / $33.9 |
| VTAMA product revenue, net | $20.7 | $55.7 | $9.2 / $14.4 |
| License, milestone and other revenue | $16.5 | $40.1 | $7.8 / $19.6 |
| Research and development expense | $123.7 | $380.8 | $125.5 / $393.4 |
| Selling, general and administrative expense | $197.3 | $517.8 | $168.3 / $475.0 |
| Net income (loss) attributable to Roivant | $5,096.2 | $4,500.0 | $(352.0) / $(975.4) |
| Net cash used in operating activities | Not presented by quarter | $(656.8) | $(664.3) |
Reported profitability primarily reflects the $5,348.4 million gain on the December sale of Telavant, rather than recurring operations. Revenue less operating expenses, before that gain, was a loss of approximately $287.5 million in the quarter and $840.4 million for the nine months. Gross margin is not a clear measure of overall business performance given the mix of product and licensing revenue and the consolidated development and commercial costs.
At December 31, 2023, cash and cash equivalents were $6,670.8 million; cash, cash equivalents and restricted cash totaled $6,685.5 million. Total current assets were $6,806.7 million and current liabilities were $244.9 million. Reported current and long-term debt totaled approximately $449.0 million, excluding lease liabilities. Total assets were $7,312.7 million and total liabilities were $728.1 million.
Material changes versus prior comparable periods
- Revenue rose to $37.1 million for the quarter from $17.1 million, and to $95.9 million for nine months from $33.9 million. Management attributed the product revenue increase mainly to higher VTAMA unit sales; license revenue growth reflected licensing activity and, year to date, a $15.0 million Dermavant milestone under its Japan Tobacco collaboration.
- VTAMA quarterly net product revenue was $20.7 million, up from $9.2 million. The filing cites a 28.5% gross-to-net yield for the quarter.
- R&D expense decreased $12.5 million year to date, primarily due to lower spending on other development and discovery programs, partly offset by increased spending on RVT-3101 and IMVT-1402. Roivant sold Telavant, which held RVT-3101 rights, to Roche in December.
- SG&A expense increased $42.8 million year to date, including higher Dermavant commercial-launch spending and employee retention-bonus expense. A $76.9 million employee cash retention program was approved in December; $35.3 million was recognized as vested and payable immediately during the nine-month period.
- Cash and cash equivalents increased from $1,676.8 million at March 31, 2023, principally following Roivant’s $5.2 billion net cash proceeds from the Telavant sale. The transaction generated $5,196.7 million of net investing cash flow for the nine-month period.
- Roivant issued shares for approximately $199.8 million net proceeds in September; Immunovant raised approximately $466.7 million net in October. Roivant’s common shares outstanding increased to 804.9 million from 760.1 million at March 31, 2023.
Outlook, management commentary, risks and unusual items
- Management stated that existing cash and cash equivalents are expected to fund committed operating expenses and capital expenditure requirements for at least 12 months from issuance of the financial statements. It expects expenses to rise as it advances research, clinical programs, VTAMA commercialization and potential in-licensing activity. No quantified earnings or revenue guidance is provided.
- Roivant may receive approximately $110 million of its share of a $150 million Telavant milestone if a Phase 3 ulcerative colitis trial is initiated. This payment is contingent and was not included in the sale gain.
- Near-term catalysts listed include an expected VTAMA atopic dermatitis supplemental application filing in the first quarter of 2024; brepocitinib uveitis data in the first quarter of 2024; batoclimab CIDP data in the second or third quarter of 2024; and later 2024–2025 trial readouts. Timings are management expectations and may change.
- In January 2024, Dermavant reported positive long-term atopic dermatitis analyses, including 51.2% of patients achieving complete disease clearance in an interim extension-trial analysis; an sNDA submission was expected that quarter. The filing cautions that preliminary clinical data may change.
- Roivant discontinued development of RVT-2001 following an interim Phase 1/2 analysis. In July and August 2023 it deconsolidated VantAI and Proteovant following transactions affecting control; the nine-month statements include a $17.4 million gain on deconsolidation.
- Key risks include clinical and regulatory uncertainty, commercialization and reimbursement execution for VTAMA, reliance on third-party manufacturers and CROs, intellectual-property challenges, and the possibility of further capital needs despite the enlarged cash balance. Management also has broad discretion over use of Telavant proceeds.
- Contingencies include Immunovant securities litigation, for which no liability was recorded because losses could not be reasonably estimated, and patent-related proceedings involving Genevant and Arbutus, including disputes concerning lipid nanoparticle patents. Roivant and affiliates intend to defend these matters.
- Controls and procedures were assessed as effective at December 31, 2023. The filing says Roivant expects to lose emerging-growth-company status and become subject to auditor attestation of internal controls beginning with its fiscal 2024 annual report.
Most important facts for investors to verify
- Whether VTAMA sales growth, payer coverage and gross-to-net performance continue, and whether the expected atopic dermatitis filing and regulatory review proceed on schedule.
- Whether the contingent Telavant Phase 3 milestone is achieved and Roivant receives its approximately $110 million share.
- Underlying cash burn and funding needs, separating recurring operations from the one-time Telavant gain and investment or fair-value movements.
- How management deploys the $6.7 billion cash balance, including acquisitions, licensing, debt actions or any capital return; the filing states there is no approved dividend plan.
- Clinical results, safety, enrollment and regulatory progress for key programs, especially batoclimab, IMVT-1402 and brepocitinib.
- Debt and future contractual obligations, including Dermavant’s NovaQuest payments, tapinarof revenue-interest obligations, minimum supply commitments and contingent milestone or royalty payments.
- Potential dilution from equity awards, subsidiary financings and sales by existing shareholders; significant shareholder lock-up agreements were stated to expire February 29, 2024.
- Developments in disclosed litigation and patent proceedings, and the company’s transition to expanded public-company reporting and internal-control requirements.